Futibatinib

CAS

1448169-71-8

INDICATION

patients with iCCA that has:

• Spread or cannot be removed by surgery
• An abnormal fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement
• Been previously treated with another therapy